<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158025">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842893</url>
  </required_header>
  <id_info>
    <org_study_id>FYL/24019/008</org_study_id>
    <nct_id>NCT01842893</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer</brief_title>
  <acronym>ETHYFYL</acronym>
  <official_title>Randomized, Placebo-controlled Study of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethypharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethypharm</source>
  <oversight_info>
    <authority>Czech Republic: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when
      used to relieve breakthrough pain (BTP) in opioid-treated cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Summed Pain Intensity Difference at 30 minutes (SPID30).</measure>
    <time_frame>30 minutes post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>SPID at 3, 6, 10, 15 and 60 minutes post-dosing</measure>
    <time_frame>3, 6, 10, 15 and 60 minutes post-dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPID at 15 and 30 minutes according to the pathophysiology of the pain (neuropathic, nociceptive)</measure>
    <time_frame>15 and 30 minutes post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference at 3, 6, 10, 15, 30 and 60 minutes after dosing</measure>
    <time_frame>3, 6, 10, 15, 30 and 60 minutes after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief at 3, 6, 10, 15, 30 and 60 minutes after dosing</measure>
    <time_frame>3, 6, 10, 15, 30 and 60 minutes after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of episodes of BTP that required rescue medication</measure>
    <time_frame>15 and 30 minutes post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of episodes with more than 33% and 50% of improvement in Pain Intensity scores</measure>
    <time_frame>15 and 30 minutes post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording of safety data</measure>
    <time_frame>During all the study duration, an expected average of 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, vital signs, urinary pregnancy test</description>
  </secondary_outcome>
  <enrollment type="Actual">91</enrollment>
  <condition>Breakthrough Pain</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Fentanyl / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After an open-label titration to identify an optimal dose, patients were randomized  to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl Ethypharm</intervention_name>
    <description>After an open-label titration to identify an optimal dose, patients were randomized  to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)</description>
    <arm_group_label>Fentanyl / Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Written informed consent

          2. Malignant solid tumor or a hematological malignancy causing cancer-related pain

          3. Background opioid treatment at a stable dose for at least a week

          4. One to four episodes of breakthrough pain per day

        Main exclusion criteria:

          1. Hypersensitivity to fentanyl or to any of the excipients

          2. Intrathecal opioids

          3. Recent history of substance abuse

          4. Recent or planned therapy that would alter pain

          5. Moderate or severe hepatic or renal disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pain Care Units</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 2, 2013</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fentanyl</keyword>
  <keyword>breakthrough pain</keyword>
  <keyword>opioid treated cancer patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
